论文部分内容阅读
细胞粘附因子ＣＤ４４的变异型（ＣＤ４４ｖ）出现在多种肿瘤的恶性转化过程中并与这些肿瘤的转移能力密切相关。然而，ＣＤ４４基因在良恶性卵巢肿瘤中的表达类型尚无定论。为此，本研究使用特异性识别ＣＤ４４分子不同抗原决定簇的单克隆抗体，对正常卵巢组织以及良性和恶性肿瘤的ＣＤ４４表达类型进行免疫组织化学分析。结果显示，ＣＤ４４ｖ在正常卵巢内呈阴性；２５例良性肿瘤中，２１例阴性，４例有灶局性变异型外显子ｖ８－ｖ１０的表达；相反，２６例卵巢癌手术切除标本和２株卵巢癌细胞系Ｃａｏｖ３和Ｏｖｃａ３有多种形式的ＣＤ４４ｖ存在；其中，ｖ７的表达明显上调。２例交界性肿瘤的表达形式与卵巢癌相似，但呈灶局阳性。本结果因而提示，ＣＤ４４ｖ尤其是ｖ７出现在卵巢癌恶性转化的过程中；它（们）可能成为该类肿瘤新的生物标志物并在癌细胞转移中起促进作用。
The variants of the cell adhesion factor CD44 (CD44v) occur in the malignant transformation of various tumors and are closely related to the metastatic capacity of these tumors. However, the expression pattern of the CD44 gene in benign and malignant ovarian tumors is inconclusive. Therefore, this study used monoclonal antibodies that specifically recognize different antigenic determinants of the CD44 molecule to perform immunohistochemical analysis of normal ovarian tissue and benign and malignant tumors. The results showed that CD44v was negative in the normal ovary; in 25 cases of benign tumors, 21 cases were negative, and 4 cases had localized variant exon v8-v10 expression; in contrast, 26 cases of surgical resection of ovarian cancer and 2 Ovarian cancer cell lines Caov3 and Ovca3 have various forms of CD44v; among them, v7 expression is significantly upregulated. The expression of borderline tumors in 2 cases was similar to that of ovarian cancer, but it was positive in the lesions. This result thus suggests that CD44v, especially v7, is in the process of malignant transformation of ovarian cancer; it may become a new biomarker for this type of tumor and play a promoting role in the metastasis of cancer cells.